Brind.

CARIS gained FDA approval for its MI Cancer Seek test and was subsequently listed on the Nasdaq stock exchange.

1 report, 1 independent Updated Aug 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

CARIS FDA Nasdaq

Keep exploring

The entities involved

CARIS
software company in Canada

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.03:29
- FDA rated generic equivalent to brand Climara Pro.03:29
Nasdaq
American fully electronic stock exchange
- Houthis attacks in Saudi Arabia prompt US diplomatic action, while quarterly results improve investor appetite.03:32
- Direct Digital is voluntarily delisting from Nasdaq following SEC regulatory actions.01:29

Coverage

Newest first; wire copies grouped

Aug 27proactiveinvestors.com